iSpecimen Inc. (NASDAQ:ISPC) Short Interest Up 186.5% in February

iSpecimen Inc. (NASDAQ:ISPC) saw a significant increase in short interest in February. As of February 13th, there was short interest totaling 900,640 shares, an increase of 186.5% from the January 29th total of 314,312 shares. Approximately 10.5% of the company’s stock are sold short. Based on an average trading volume of 2,898,153 shares, the short-interest ratio is currently 0.3 days. Based on an average trading volume of 2,898,153 shares, the short-interest ratio is currently 0.3 days. Approximately 10.5% of the company’s stock are sold short.

Hedge Funds Weigh In On iSpecimen

A hedge fund recently bought a new stake in iSpecimen stock. Scientech Research LLC acquired a new position in shares of iSpecimen Inc. (NASDAQ:ISPC) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned about 0.30% of iSpecimen as of its most recent filing with the Securities and Exchange Commission (SEC). 13.62% of the stock is currently owned by institutional investors.

iSpecimen Price Performance

ISPC opened at $0.27 on Thursday. The company’s 50-day moving average is $0.33 and its 200 day moving average is $0.68. iSpecimen has a fifty-two week low of $0.23 and a fifty-two week high of $3.18. The firm has a market capitalization of $2.63 million, a P/E ratio of -0.03 and a beta of 1.84.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of iSpecimen in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

About iSpecimen

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.